NEW YORK (TheStreet) -- The recent partnership between GlaxoSmithKline (GSK) - Get Report and Alphabet (GOOGL) further opens the door for development in the biotechnology industry's experimental "bioelectronics" segment.

Chairman of Vaccines at GlaxoSmithKline Dr. Moncef Slaoui thinks the partnership could create an entirely new industry.

"I think this is a whole new industry as big as the pharmaceutical industry ... there's a whole new world that we're opening here which is dealing with electrical signals to connect with our biology and changes functioning," Slaoui told CNBC's Meg Tirrell on "Squawk Box" Monday morning.

Calling Alphabet's Verily Life Services a "really exciting partner," Slaoui says GlaxoSmithKline shares "a very common vision of integrating electronics and big data analytics and technologies with medicines and biology."

"They bring to us the engineering capabilities, the electronics, the low power technologies and the wireless technologies that are critical to miniaturize these devices, power them and extract information from them," Slaoui noted.

Slaoui cited animal models as the indicator that bioelectronics can treat chronic diseases with a number of different devices. The devices themselves are very small, about "the size of a rice grain", and can "either stimulate or black the electric signals that our brains sense through our nerves to control the functioning of our organs," Slaoui stated.

"The limitations are around power as power requires energy and energy means heat and heat doesn't go well with biology," Slaoui added.

Shares of of GlaxoSmithKline are up by 0.22% to $45.17 in late morning trading today. 

Separately, TheStreet Ratings teams rates GlaxoSmithKline as a "hold" with a ratings score of C. 

The primary factors that have impacted TheStreet's rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its good cash flow from operations, expanding profit margins and solid stock price performance. However, as a counter to these strengths, TheStreet Ratings team also finds weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity.

TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

You can view the full analysis from the report here: GSK

Image placeholder title